Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.320 -0.050 (-3.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
News headline image
The 5 Top Stocks Cathie Wood Is Buying Now ↗
Cathie Wood's ETFs have performed well following the release of July's CPI report. Recent Cathie Wood stocks include NVTA, TDOC and RBLX. 
Via InvestorPlace
News headline image
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock ↗
FATE stock is in focus after Cathie Wood's Ark Invest purchased over 600,000 shares yesterday. This was Ark's first purchase since February. 
Via InvestorPlace
News headline image
Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock ↗
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds... 
Via Benzinga
News headline image
Fate Therapeutics Initiated With Hold Rating - Read Why ↗
 
Via Benzinga
News headline image
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock ↗
 
Via Benzinga
News headline image
Expert Ratings for Fate Therapeutics ↗
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: 
Via Benzinga
News headline image
Recap: Fate Therapeutics Q1 Earnings ↗
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday ↗
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
7 Small-Cap Stocks to Buy Before the Bull Market Returns ↗
These small-cap stocks to buy before the bull market returns have underperformed the market, but have immense potential for future gains. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗
  
Via Benzinga
News headline image
7 Cathie Wood Stocks Trading at a Discount Right Now ↗
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments. 
Via InvestorPlace
News headline image
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
7 Small-Cap Stocks to Buy in July 2022 ↗
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments? ↗
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Fate Therapeutics ↗
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
News headline image
Fate Therapeutics: Q4 Earnings Insights ↗
Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Fate Therapeutics's Earnings: A Preview ↗
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
Earnings Outlook For Fate Therapeutics ↗
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch ↗
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century... 
Via Benzinga
News headline image
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? ↗
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today ↗
Fate Therapeutics (NASDAQ:FATE) has outperformed the market over the past 5 years by 64.83% on an annualized basis. Buying $100 In FATE: 5 years ago, an investor could have... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.